Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1/2013

01.05.2013

C-reactive protein and the biology of disease

verfasst von: Waliza Ansar, Shyamasree Ghosh

Erschienen in: Immunologic Research | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The C-reactive protein (CRP) is a plasma protein of hepatic origin, belonging to pentraxin family and forms a major component of any inflammatory reaction. A key component of the innate immunity pathway, the concentration of CRP may rapidly increase to levels more than 1,000-folds above normal values as a consequence to tissue injury or infection. Although functioning as a classical mediator of innate immunity, it functions via interaction of components of both humoral and cellular effector systems of inflammation. Initially considered as an acute-phase marker in tissue injury, infection and inflammation, it now has a distinct status of a disease marker in cardiovascular diseases and is well known of its clinical and pathological significance. The present torrent of studies in a large number of diseases and associated conditions has highly elucidated the role of CRP as a therapeutic and research reagent. In this review, we focus our attention to role of CRP in health and disease. The future prospect of this review lies in the applicability of CRP as a molecule in understanding and monitoring of the biology of disease.
Literatur
1.
Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–71.PubMedCrossRef
2.
Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. J Exp Med. 1941;73:183–90.PubMedCrossRef
3.
Abernethy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. 1. Distribution of the reactive protein in patient’s sera and the effect of calcium on the flocculation reaction with C polysaccharide of Pneumococcus. J Exp Med. 1941;73:173–82.PubMedCrossRef
4.
Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406–18.PubMedCrossRef
5.
Li YP, Mold C, Du Clos TW. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol. 1994;152:2995–3005.PubMed
6.
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–97.PubMedCrossRef
7.
8.
Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol. 1989;143:2553–9.PubMed
9.
Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol. 1988;141:4266–70.PubMed
10.
Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.PubMedCrossRef
11.
Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature. 1978;273:168–70.PubMedCrossRef
12.
Robey FA, Liu TY. Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem. 1981;256:969–75.PubMed
13.
Olafsen JA. Role of lectins (C-reactive protein) in defense of marine bivalves against bacteria. Adv Exp Med Biol. 1995;371A:343–8.PubMedCrossRef
14.
Nagpurkar A, Mookerjea S. A novel phosphorylcholine-binding protein from rat serum and its effect on heparin-lipoprotein complex formation in the presence of calcium. J Biol Chem. 1981;256:7440–6.PubMed
15.
De Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods. 1982;50:17–31.PubMedCrossRef
16.
De Beer FC, Shine B, Pepys MB. Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol. 1982;50:231–7.PubMed
17.
Mandal C, Sinha S, Mandal C. Lectin like properties and differential sugar binding characteristics of C-reactive proteins purified from sera of normal and pollutant induced Labeo rohita. Glycoconj J. 1999;16:741–50.PubMedCrossRef
18.
Sinha S, Mandal C. Microheterogeneity of C-reactive protein in the sera of fish Labeo rohita induced by metal pollutants. Biochem Biophys Res Commun. 1996;226:681–7.PubMedCrossRef
19.
Paul I, Mandal C, Allen AK, Mandal C. Glycosylated molecular variants of C-reactive proteins from the major carp Catla catla in fresh and polluted aquatic environments. Glycoconj J. 2001;18:547–56.PubMedCrossRef
20.
21.
McCarty M. The occurrence during acute infections of a protein not normally present in the blood: IV. Crystallization of the C-reactive protein. J Exp Med. 1947;85:491–8.PubMedCrossRef
22.
Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med. 1966;123:365–78.PubMedCrossRef
23.
Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996;156:4815–20.PubMed
24.
Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039–51.PubMedCrossRef
25.
Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001;69:1747–54.PubMedCrossRef
26.
Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152–61.PubMedCrossRef
27.
Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest. 1994;94:1390–6.PubMedCrossRef
28.
Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol. 1995;155:2185–93.PubMed
29.
Das T, Sen A, Kempf T, Pramanik SR, Mandal C, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J. 2003;373:345–55.PubMedCrossRef
30.
Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370–1.PubMedCrossRef
31.
Ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 1990;17:1642–8.PubMed
32.
33.
Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–9.PubMedCrossRef
34.
Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMedCrossRef
35.
Chandrashekara S, Sachin S. Measures in rheumatoid arthritis: are we measuring too many parameters. Int J Rheum Dis. 2012;15:239–48.PubMedCrossRef
36.
Galeazzi M, Morozzi G, Veronesi M, Ronconi S, Magi B, Bini L, et al. Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis. Recenti Prog Med. 1995;86:456–62.PubMed
37.
Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:782–5.PubMed
38.
Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994;24:91–104.PubMedCrossRef
39.
Vogt B, Führnrohr B, Müller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity. 2007;40:295–8.PubMedCrossRef
40.
Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008;59:1814–20.PubMedCrossRef
41.
Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus. 2011;20:1494–500.PubMedCrossRef
42.
Olson RE. Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr. 2000;47:55–78.PubMed
43.
Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly. 2008;138:534–9.PubMed
44.
Danesh J, Pepys MB. C-reactive protein in healthy and in sick populations. Eur Heart J. 2000;21:1564–5.PubMedCrossRef
45.
Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.PubMed
46.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of stain therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.PubMedCrossRef
47.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation. 1999;100:230–5.PubMedCrossRef
48.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
49.
Emerging Risk Factor Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.PubMedCrossRef
50.
Kushner I, Rakita L, Kaplan MH. Studies of acute phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest. 1963;42:286–92.PubMedCrossRef
51.
Kushner I, Kaplan MH. Antigenic analysis of extracts of human heart tissue: cardiac antigens with limited distribution in other organs. J Immunol. 1967;99:526–33.PubMed
52.
53.
Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733–9.PubMedCrossRef
54.
de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002;317:1–15.PubMedCrossRef
55.
Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635–41.PubMedCrossRef
56.
Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, et al. C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes. 15 Oct 2012. [in press].
57.
Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010;6:27–34.PubMedCrossRef
58.
King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535–9.PubMedCrossRef
59.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.PubMedCrossRef
60.
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef
61.
Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:R55.PubMedCrossRef
62.
Helzlsouer KJ, Erlinger TP, Platz EA. Creactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer. 2006;42:704–7.PubMedCrossRef
63.
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.PubMedCrossRef
64.
Ansar W, Bandyopadhyay SM, Chowdhury S, Habib SH, Mandal C. Role of C-reactive protein in complement mediated hemolysis in malaria. Glyconj J. 2006;23:233–40.CrossRef
65.
Dongho Dongmo FF, Ngono Ngane RA, Gouado I, Pankoui Mfonkeu JB, Mbackop Kwemba V, et al. Predictors of childhood severe malaria in a densely populated area: Douala, Cameroon. Afr J Biotechnol. 2011;10:6319–24.
66.
Nahrevanian H, Gholizadeh J, Farahmand M, Assmar M. Patterns of co-association of C-reactive protein and nitric oxide in malaria in endemic areas of Iran. Mem Inst Oswaldo Cruz. 2008;103:39–44.PubMedCrossRef
67.
Bourée P, Botterel F, Lançon A. Comparative study VS-CRP in malaria. Mal. Inf. Dis. Afr. 2000;2–3.
68.
Kremsner PG, Winkler S, Wildling E, Prada J, Bienzlz U, Graninger W, Nüssler AK. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitogical and clinical cure in Plasmodium falciparum malaria. Trans R Trop Med Hyg. 1996;90:44–7.CrossRef
69.
Paul R, Sinha PK, Banerjee AK, Raychaudhuri P, Mondal J. Study of C reactive protein as a prognostic marker in malaria from Eastern India. Adv Biomed Res. 2012;1:1–9.CrossRef
70.
Gjørup IE, Vestergaard LS, Møller K, Rønn AM, Bygbjerg IC. Laboratory indicators of the diagnosis and course of imported malaria. Scand J Infect Dis. 2007;39:707–13.PubMedCrossRef
71.
Jakobsen PH, Mckay V, Jie RN, Olaleye BO, D’alessandro U, Zhang GH, et al. Decreased antitoxic activities among children with clinical episodes of malaria. Infect Immun. 1998;66:1654–9.PubMed
72.
Ansar W, Mandal C, Habib Sk, Roy S, Mandal C. Unraveling the C-reactive protein complement-cascade in destruction of red blood cells: potential pathological implications in Plasmodium falciparum malaria. Cell Physiol Biochem. 2009;23:169–75.CrossRef
73.
Culley FJ, Harris RA, Kaye PM, McAdam KP, Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol. 1996;156:4691–6.PubMed
74.
Culley FJ, Thomson M, Raynes JG. C-reactive protein increases C3 deposition on Leishmania donovani promastigotes in human serum. Biochem Soc Trans. 1997;25:286S.PubMed
75.
Culley FJ, Bodman-Smith KB, Ferguson MA, Nikolaev AV, Shantilal N, Raynes JG. C-reactive protein binds to phosphorylated carbohydrates. Glycobiology. 2000;10:59–65.PubMedCrossRef
76.
Bodman-Smith KB, Mbuchi M, Culley FJ, Bates PA, Raynes JG. C-reactive protein-mediated phagocytosis of Leishmania donovani promastigotes does not alter parasite survival or macrophage responses. Parasite Immunol. 2002;24:447–54.PubMedCrossRef
77.
Bee A, Culley FJ, Alkhalife IS, Bodman-Smith KB, Raynes JG, Bates PA. Transformation of Leishmania mexicana metacyclic promastigotes to amastigote-like forms mediated by binding of human C-reactive protein. Parasitology. 2001;122:521–9.PubMedCrossRef
78.
Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. Clin Immunol. 2007;122:343–8.PubMedCrossRef
79.
Ansar W, Mukhopadhyay S, Habib SK, Basu S, Saha B, Sen AK, et al. Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J. 2009;26:1151–69.PubMedCrossRef
80.
Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96:793–807.PubMedCrossRef
81.
Gasim S, Theander TG, ElHassan AM. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Trop. 2000;75:35–8.PubMedCrossRef
82.
de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47:239–43.PubMedCrossRef
83.
Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011;162:597–605.PubMedCrossRef
84.
Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212.PubMedCrossRef
85.
Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, et al. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods. 2012;384:92–102.PubMedCrossRef
86.
Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169–77.PubMedCrossRef
Metadaten
Titel
C-reactive protein and the biology of disease
verfasst von
Waliza Ansar
Shyamasree Ghosh
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Immunologic Research / Ausgabe 1/2013
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8384-0

Weitere Artikel der Ausgabe 1/2013

Immunologic Research 1/2013 Zur Ausgabe

OriginalPaper

Adjuvant dependence of APS pathology-related low-affinity antibodies during secondary immune response to tetanus toxoid in BALB/c mice

OriginalPaper

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer

OriginalPaper

Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency

OriginalPaper

Potential regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood

OriginalPaper

The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity

OriginalPaper

Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise